...Neurology, Drug delivery Hired: Kenneth Gayron as VP and CFO, formerly VP and treasurer at Sensus...

...Calif. Business: Metabolic Hired: John Scarlett as president, CEO and a director, formerly CEO of Sensus...

...Sixty Inc. , Houston, Texas Business: Chemistry Hired: Robert Davis as CEO, formerly EVP at Sensus...

...Pharmacogenetics Hired: William Bennett as SVP of research, formerly SVP of research and manufacturing at Sensus...

...option to acquire the 81.1 percent of Sensus it did not already own. Last month, Sensus...
...The product has Orphan Drug designation and priority review status. PHA acquired 19.9 percent of Sensus...
...company received the option to acquire the remainder of Sensus (see BioCentury, June 21, 1999). Sensus...

...Total symptoms and signs of acromegaly decreased significantly in all Somavert groups as well (p?0.05). Sensus...

...Sensus licensed Shearwater's polyethylene glycol (PEG) technology for the pegylation of Sensus' Somavert pegvisomant (formerly Trovert...
...19.9 percent of Sensus and has an option to acquire the rest of the company. Sensus...

...position. Sensus’ pegvisomant growth hormone receptor antagonist has completed Phase III testing to treat acromegaly. Sensus...

...a normalization of IGF-I. Data were presented at the Endocrine Society meeting in San Diego. Sensus...